The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGlu 1 receptor antagonist

Journal of Physiology and Pharmacology

Volumn 55, Issue 1 I, 2004, Pages 113-126

  Klodzinska A ^a   Tatarczynska E ^a   Stachowicz, K ^a   Chojnacka Wojcik E ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

AIDA; Anxiolytic like activity; Metabotropic glutamate receptors; mGlu1 receptor antagonist; Mice; Rats

Indexed keywords

1 AMINO 1,5 INDANDICARBOXYLIC ACID; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; COMPETITIVE INHIBITION; CONFLICT; CONTROLLED STUDY; DOSE RESPONSE; DRINKING; DRUG SELECTIVITY; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MAZE TEST; MOTOR COORDINATION; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; RAT; SHOCK; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CONFLICT (PSYCHOLOGY); DIAZEPAM; DISCRIMINATION LEARNING; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ELECTRIC STIMULATION; EXPLORATORY BEHAVIOR; INDANS; INJECTIONS, INTRAPERITONEAL; MALE; MAZE LEARNING; MICE; MOTOR ACTIVITY; PHYSICAL ENDURANCE; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; WATER DEPRIVATION;

EID: 1942425046     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Monaghan DT, Bridges RJ, Cotman CW. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Ann Rev Pharmacol Toxicol 1989; 29: 365-402.
2. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995; 34: 1-26.
3. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Ann Rev Pharmacol Toxicol 1997; 37: 205-237.
4. Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F. Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death. Eur J Pharmacol 1994; 256: 109-112.
5. Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T. Metabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders? Trends Neurosci 1996; 19: 267-271.
6. Chojnacka-Wójcik E, Kłodzińska A, Pilc A. Glutamate receptor ligands as anxiolytics. Curr Opin Invest Drugs 2001; 2: 1112-1119.
7. Pilc A, Kłodzińska A, Nowak G. A role for glutamate in the treatment of anxiety and depression: focus on group I metabotropic glutamate (mGlu) receptor. Drugs of the Future 2002; 27: 1-11.
8. Chojnacka-Wójcik E, Tatarczyńska E, Pilc A. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. Eur J Pharmacol 1997; 319: 153-156.
9. Monn JA, Valli MJ, Massey SM et al. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo [3.1.0.]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 1997; 40: 528-537.
10. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ. Anxiolytic and side-effect profile of LY 354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 1998; 284: 651-660.
11. Kłodzińska A, Chojnacka-Wójcik E, Pałucha A, Brański P, Popik P, Pilc A. Potential antianxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 1999; 38: 1831-1839.
12. Tatarczyńska E, Kłodzińska A, Chojnacka-Wó jcik E et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001; 132: 1423-1430.
13. Tatarczyńska E, Kłodzińska A, Kroczka B, Chojnacka-Wójcik E, Pilc A. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology 2001; 158: 94-99.
14. Pilc A, Kłodzińska A, Brański P et al. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 2002; 43: 181-187.
15. Spooren WPJM, Schoeffter P, Gasparini F, Kuhn R, Gentsch K. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY 314582, MPEP and NKP608). Eur J Pharmacol 2002; 435: 161-170.
16. Gasparini F, Lingenhohl K, Stoehr N et al. 2-methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999; 38: 1493-1503.
17. Kłodzińska A, Tatarczyńska E, Chojnacka-Wó jcik E, Pilc A. Anxiolytic-like effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) in rats. Pol J Pharmacol 2000; 52: 463-466.
18. Spooren WPJM, Vassout A, Neijt HC et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 2000; 295: 1267-1275.
19. Pellicciari R, Luneia R, Costantino G et al. 1-Aminoindan-1,5-dicarboxylic acid: a novel antagonist at phospholipase C-linked metabotropic glutamate receptors. J Med Chem 1995; 38: 3717-3719.
20. Costantino G, Pellicciari R. Homology modeling of metabotropic glutamate receptors (mGluRs): structural motifs affecting binding modes and pharmacological profile of mGluR1 agonist and competitive antagonists. J Med Chem 1996; 39: 3998-4006.
21. Moroni F, Lombardi G, Thomsen C et al. Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonist. J Pharmacol Exp Ther 1997; 281: 721-729.
22. Hermans E, Challiss RAJ, Nahorski SR. Effects of varying the expression level of recombinant human mGlu1α receptors on the pharmacological properties of agonists and antagonist. Br J Pharmacol 1999; 126: 873-882.
23. Thomsen C, Dalby NO. Roles of metabotropic glutamate receptor subtypes in modulation of pentylenetetrazole-induced seizure activity in mice. Neuropharmacology 1998; 37: 1465-1473.
24. Chapman AG, Yip PK, Yap JS et al. Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Eur J Pharmacol 1999; 368: 17-24.
25. Pellegrini-Giampietro DE, Peruginelli F, Meli E et al. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms. Neuropharmacology 1999; 38: 1607-1619.
26. Mills CD, Xu GY, Johnson KM, McAdoo DJ, Hulsebosch CE. AIDA reduces glutamate release and attenuates mechanical allodynia after spinal cord injury. Neuroreport 2000; 11: 3067-3070.
27. Wolfarth S, Konieczny J, Lorenc-Koci E, Ossowska K, Pilc A. The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity. Amino Acids 2000; 19: 95-101.
28. Car H, Nadlewska A, Oksztel R, Wiśniewski K. AIDA influences behavior in rats pretreated with baclofen. Pol J Pharmacol 2001; 53: 245-252.
29. Cozzi A, Meli E, Carla V, Pellicciari R, Moroni F, Pellegrini-Giampietro DE. Metabotropic glutamate 1 (mGlu1) receptor antagonists enhance GABAergic neuro-transmission: a mechanism for the attenuation of post-ischemic injury and epileptiform activity? Neuropharmacology 2002; 43: 119-130.
30. Dolan S, Nolan AM. Behavioral evidence supporting a differential role for spinal group I and II metabotropic glutamate receptors in inflammatory hyperalgesia in sheep. Neuropharmacology 2002; 43: 319-326.
31. Nielsen KS, Macphail EM, Riedel G. Class I mGlu receptor antagonist 1-aminoindan-1,5-dicarboxylic acid blocks contextual but not cue conditioning in rats. Eur J Pharmacol 1997; 326: 105-108.
32. Christoffersen GRJ, Christensen LH, Harrington NR, Macphail EM, Riedel G. Task-specific enhancement of short-term, but not long-term, memory by class I metabotropic glutamate receptor antagonist 1-aminoindan-1,5-dicarboxylic acid in rats. Behav Brain Res 1999; 101: 215-226.
33. Rao AM, Hatcher JF, Dempsey RJ. Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil. Neurosci Lett 2000; 293: 1-4.
34. Vogel JR, Beer B, Clody DE. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 1971; 21: 1-7.
35. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 1986; 24: 525-529.
36. Aron C, Simon P, Larousse C, Boissier JR. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 1971; 10: 459-469.
37. Janssen PA, Jageneau AH, Schellekens KH. Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone. IV. Influence of haloperidol (R 1625) and of chlorpromazine on the behaviour of rats in an unfamiliar 'open field' situation. Psychopharmacologia 1960; 1: 389-392.
38. Pollard GT, Howard JL. Effects of drugs on punished behavior: pre-clinical test for anxiolytics. Pharmacol Ther 1990; 45: 403-424.
39. Dawson GR, Tricklebank MD. Use of the elevated plus-maze in the search for novel anxiolytic agents. Trends Pharmacol Sci 1995; 16: 33-36.
40. Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E. Anticonflict effect of ipsapirone, buspirone and gepirone is not mediated by their common metaboilte 1-(2-pyrimidinyl)piperazine. J Psychopharmacol 1989; 3: 180-185.
41. Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E. Anxiolytic- and antidepressant-like effects of an antagonist at glycineB receptors. Pol J Pharmacol 1998; 50: 349-354.
42. Belzung C. Rodent models of anxiety-like behaviors: Are they predictive for compounds acting via non-benzodiazepine mechanisms? Curr Opin Invest Drugs 2001; 2: 1108-1111.
43. 3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur J Pharmacol 2003; 473: 35-40.
44. Bordi F, Ugolini A. Group I metabotropic glutamate receptors: implications for brain diseases. Prog Neurobiol 1999; 59: 55-79.
45. Masu M, Tanabe Y, Tsuchida K, Shigemoto R, Nakanishi S. Sequence and expression of a metabotropic glutamate receptor. Nature 1991; 349: 760-765.
46. 2+ signal transoluction. J Biol Chem 1992; 267: 13361-13368.
47. Martin LJ, Blackstone CD, Huganir RL, Price DL. Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 1992; 9: 259-270.
48. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N. Immunohistochemical localization of a metabotropic glutamate receptor mGluR5, in the rat brain. Neurosci Lett 1993; 163: 53-57.
49. Testa CM, Friberg IK, Weiss SW, Standaert DG. Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGlu2/3 in the rat basal ganglia. J Comp Neurol 1998; 390: 5-19.
50. Gray JA. Precis of the neuropsychology of anxiety: an enquiry into the functions of the septohippocampal system. Behav Brain Sci 1982; 5: 469-534.
51. Haefely W, Kulcsar A, Mohler H, Pieri L, Polc P, Schaffner R. Possible involvement of GABA in the central actions of benzodiazepines. Adv Biochem Psychopharmacol 1975; 14: 131-151.